CD274 and non-small cell lung carcinoma: The patients (n = 541) with stage IV or recurrent NSCLC harboring PD-L1 positive tumors (PD-L1 ≥ 1%) were randomly recruited and grouped in a 1:1 ratio to either receive nivolumab or platinum-based chemotherapy.